A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Open accessAbstract
The tumor microenvironment provides unique challenges for the delivery of chemotherapeutic agents in doses that are effective while ensuring minimal systemic toxicity. The primary limitation of current therapeutics is a lack of specificity in delivery, as they target healthy and cancerous cells alike. The development of nanoscale carriers capable of delivering cancer therapies has the potential to overcome both systemic and tumor barriers and provide specific, targeted delivery. This review seeks to provide an overview of available nanoscale drug carriers by exploring the wide variety of developed nanostructures and the most commonly used moieties for targeted delivery. Additionally, the use of nanoscale carriers will be motivated by examining tumor physiology and the specific barriers present within both the tumor microenvironment and systemic delivery.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many types of ligands, such as folate, transferrin, antibody and aptamer, can be incorporated into non-viral vectors to boost cellular uptake via receptor-mediated endocytosis.
“Meanwhile, many types of ligands, such as folate, transferrin, antibody and aptamer, etc., can also be incorporated into the non-viral vectors to boost cellular uptake via receptor-mediated endocytosis [171–173].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Biomaterials Science: An Introduction to Materials in Medicine
Ratner, B. D., Hoffman, A. S., Schöen, F. J., & Lemons, J. E. (1996) · doi:10.1016/c2009-0-02433-7 · Cited by 5,125 · see citing works
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · see citing works
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,784 · see citing works
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · see citing works
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637 · see citing works
Self-citationThe dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,273 · see citing works
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,040 · see citing works
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918 · see citing works
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495 · see citing works
Nanoparticle and targeted systems for cancer therapy
Brannon‐Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,335 · see citing works
Chithrani, D. B., & Chan, W. C. W. (2007) · Nano Letters · doi:10.1021/nl070363y · Cited by 2,274 · see citing works
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262 · see citing works
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon‐Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,732 · see citing works
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,498 · see citing works
Targeted drug delivery via the folate receptor
Sudimack, J. J., & Lee, R. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00062-9 · Cited by 1,477 · see citing works
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,357 · see citing works
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc749 · Cited by 1,350 · see citing works
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,254 · see citing works
In Vitro Selection of Functional Nucleic Acids
Wilson, D. S., & Szostak, J. W. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.611 · Cited by 1,209 · see citing works
Roberts, W. G., & Palade, G. E. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.6.2369 · Cited by 1,039 · see citing works
Dhar, S., Gu, F., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994 · see citing works
Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers
Dreher, M. R., Liu, W., Michelich, C. R., Dewhirst, M. W., Yuan, F., & Chilkoti, A. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj070 · Cited by 911 · see citing works
Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
Storm, G., Belliot, S. O., Daemen, T., & Lasiç, D. D. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00039-a · Cited by 878 · see citing works
Novel applications of liposomes
Lasiç, D. D. (1998) · Trends in biotechnology · doi:10.1016/s0167-7799(98)01220-7 · Cited by 865 · see citing works
Direct Fabrication and Harvesting of Monodisperse, Shape-Specific Nanobiomaterials
Rolland, J. P., Maynor, B. W., Euliss, L. E., Exner, A. E., Rothrock, G. D., & DeSimone, J. M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051977c · Cited by 849 · see citing works
Block copolymer micelles as long-circulating drug vehicles
Kwon, G. S., & Kataoka, K. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00031-2 · Cited by 825 · see citing works
Nanoparticles for drug delivery in cancer treatment
Haley, B., & Frenkel, E. P. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.03.015 · Cited by 805 · see citing works
Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery
Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00015-7 · Cited by 756 · see citing works
Making polymeric micro- and nanoparticles of complex shapes
Champion, J. A., Katare, Y. K., & Mitragotri, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705326104 · Cited by 748 · see citing works
Cisplatin and platinum drugs at the molecular level (Review)
Boulikas, T., & Vougiouka, M. (2003) · Oncology Reports · doi:10.3892/or.10.6.1663 · Cited by 730 · see citing works
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, E. K. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 724 · see citing works
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 696 · see citing works
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625 · see citing works
Folate receptor targeted biodegradable polymeric doxorubicin micelles
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.003 · Cited by 620 · see citing works
The transferrin receptor: role in health and disease
Ponka, P., & Lok, C. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00070-9 · Cited by 598 · see citing works
Majoros, I., Myc, A., Thomas, T. P., Mehta, C. B., & Baker, J. R. (2006) · Biomacromolecules · doi:10.1021/bm0506142 · Cited by 597 · see citing works
Nanostructure-mediated drug delivery
Hughes, G. A. (2005) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2004.11.009 · Cited by 561 · see citing works
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558 · see citing works
Targeted nanoparticles for cancer therapy
Gu, F., Karnik, R., Wang, A. Z., Alexis, F., Levy‐Nissenbaum, E., Hong, S., Langer, R., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 512 · see citing works
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lü, D., & Au, J. L. ‐. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 491 · see citing works
Venturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 463 · see citing works
cRGD‐Functionalized Polymer Micelles for Targeted Doxorubicin Delivery
Nasongkla, N., Shuai, X., Ai, H., Weinberg, B. D., Pink, J. J., Boothman, D. A., & Gao, J. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200460800 · Cited by 434 · see citing works
New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy
Park, K., Lee, S., Kang, E., Kim, K., Choi, K., & Kwon, I. C. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200801655 · Cited by 430 · see citing works
Fang, C., Shi, B., Pei, Y., Hong, M., Wu, J., & Chen, H. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.08.002 · Cited by 424 · see citing works
Targeted Nanoparticles for Cancer Therapy
Reddy, G. S. N. (2021) · Journal of Bioanalysis & Biomedicine · Cited by 401 · see citing works
Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.044 · Cited by 384 · see citing works
Feng, S., & Chien, S. (2003) · Chemical Engineering Science · doi:10.1016/s0009-2509(03)00234-3 · Cited by 364 · see citing works
Transporter-Mediated Permeation of Drugs Across the Blood–Brain Barrier
Tamai, I., & Tsuji, A. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200011)89:11 · Cited by 363 · see citing works
Sahoo, S. K., & Labhasetwar, V. (2005) · Molecular Pharmaceutics · doi:10.1021/mp050032z · Cited by 340 · see citing works
Sahoo, S. K., Ma, W., & Labhasetwar, V. D. (2004) · International Journal of Cancer · doi:10.1002/ijc.20405 · Cited by 327 · see citing works
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 311 · see citing works
Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers
Caldorera‐Moore, M. E., Guimard, N. K., Shi, L., & Roy, K. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903579971 · Cited by 303 · see citing works
Self-citationCaldorera‐Moore, M. E., Liechty, W. B., & Peppas, N. A. (2011) · Accounts of Chemical Research · doi:10.1021/ar2001777 · Cited by 302 · see citing works
Self-citationTargeted nanodelivery of drugs and diagnostics
Phillips, M. A., Gran, M. L., & Peppas, N. A. (2010) · Nano Today · doi:10.1016/j.nantod.2010.03.003 · Cited by 297 · see citing works
Self-citationWeber, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 284 · see citing works
Glangchai, L. C. S., Caldorera‐Moore, M. E., Shi, L., & Roy, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.021 · Cited by 239 · see citing works
Self-citationControl of tumour vascular permeability
Baban, D. F., & Seymour, L. W. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00003-9 · Cited by 237 · see citing works
Dellian, M., Witwer, B. P., Salehi, H. A., Yuan, F., & Jain, R. K. (1996) · Europe PMC (PubMed Central) · Cited by 232 · see citing works
Expert opinion: Responsive polymer nanoparticles in cancer therapy
Liechty, W. B., & Peppas, N. A. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.08.004 · Cited by 226 · see citing works
Self-citationMicro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems
Caldorera‐Moore, M. E., & Peppas, N. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.09.002 · Cited by 217 · see citing works
Self-citationWu, J., Akaike, T., & Maeda, H. (1998) · PubMed · Cited by 212 · see citing works
Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries
Krag, D. N., Shukla, G. S., Shen, G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4441 · Cited by 212 · see citing works
Monoclonal Antibody Therapy for Cancer
von Mehren, M., Adams, G. P., & Weiner, L. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152442 · Cited by 191 · see citing works
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00237-x · Cited by 186 · see citing works
Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue
Matsumura, Y., Kimura, M., Yamamoto, T., & Maeda, H. (1988) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1988.tb01563.x · Cited by 163 · see citing works
Biodegradable Nanoparticles for Direct or Two-Step Tumor Immunotargeting
Nobs, L., Buchegger, F., Gurny, R., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050137k · Cited by 135 · see citing works
cRGD‐Functionalized Polymer Micelles for Targeted Doxorubicin Delivery
Nasongkla, N., Shuai, X., Ai, H., Weinberg, B. D., Pink, J. J., Boothman, D. A., & Gao, J. (2004) · Angewandte Chemie · doi:10.1002/ange.200460800 · Cited by 105 · see citing works
New approaches to antibody therapy
Weiner, L. M., & Adams, G. P. (2000) · Oncogene · doi:10.1038/sj.onc.1204000 · Cited by 89 · see citing works
Johnston, A. P. R., Kamphuis, M. M. J., Such, G. K., et al. (2012) · ACS Nano · doi:10.1021/nn3010476 · Cited by 85 · see citing works
New developments in angiogenesis: a major mechanism for tumor growth and target for therapy.
Jones, A., & Harris, A. L. (1998) · PubMed · Cited by 83 · see citing works
Hoffmann, T. K., Häfner, D., Balló, H., et al. (1998) · PubMed · Cited by 68 · see citing works
Schoener, C. A., Hutson, H. N., & Peppas, N. A. (2012) · Polymer International · doi:10.1002/pi.4219 · Cited by 66 · see citing works
Self-citationCaldorera‐Moore, M. E., Kang, M. K., Moore, Z., Singh, V., Sreenivasan, S. V., Shi, L., Huang, R., & Roy, K. (2011) · Soft Matter · doi:10.1039/c0sm01185a · Cited by 57 · see citing works
Self-citationMoghimi, S. M., Hedeman, H., Christy, N. M., Ilium, L., & Davis, S. S. (1993) · Journal of Leukocyte Biology · doi:10.1002/jlb.54.6.513 · Cited by 53 · see citing works
Identification of cancer targets and therapeutics using phage display.
Brissette, R. E., Prendergast, J. K. A., & Goldstein, N. I. (2006) · PubMed · Cited by 53 · see citing works
Liechty, W. B., Caldorera‐Moore, M. E., Phillips, M. A., Schoener, C. A., & Peppas, N. A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.009 · Cited by 50 · see citing works
Self-citationCharacterization of Heterogeneous Distribution of Tumor Blood Flow in the Rat
Hori, K., Suzuki, M., Tanda, S., et al. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01753.x · Cited by 31 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Caldorera-Moore M Peppas NA Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems Adv Drug Delivery Rev 2009b 61 1391 1401 PMC2788786 19758574
- Janson CG During MJ Liang KW Liu F Huang L Targeted Gene Delivery Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules 2006 Springer US 30 37
- Peppas NA Slaughter BV Kanzelberger MA Hydrogels in Polymer Science: A Comprehensive Reference 2012 Amsterdam Elsevier
- Ratner BD Hoffman AS Schoen FJ Lemons JE Biomaterials Science, Second Edition: An Introduction to Materials in Medicine 2004 San Diego Elsevier Academic Press
Cited by
Sorted by citations
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164 · see citing works
Stimulus-responsive hydrogels: theory, modern advances, and applications
Koetting, M. C., Peters, J. T., Steichen, S. D., & Peppas, N. A. (2015) · Materials Science and Engineering: R: Reports · doi:10.1016/j.mser.2015.04.001 · Cited by 1,191 · see citing works
Self-citationPharmacokinetic aspects of retinal drug delivery
del Amo, E. M., Rimpelä, A.-K., Heikkinen, E., Kari, O. K., Ramsay, E., Lajunen, T., Schmitt, M., Pelkonen, L., Bhattacharya, M., Richardson, D., et al. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.12.001 · Cited by 693 · see citing works
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415 · see citing works
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350 · see citing works
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273 · see citing works
Biomaterial‐Based Implantable Devices for Cancer Therapy
Chew, S. A., & Danti, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600766 · Cited by 121 · see citing works
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82 · see citing works
Samani, R. K., Tavakoli, M. B., Maghsoudinia, F., Motaghi, H., Hejazi, S. H., & Mehrgardi, M. A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105487 · Cited by 40 · see citing works
Patel, A., Patel, M., Saha, N., Patel, S., Ahlawat, P., & Dharamsi, A. (2022) · Recent Advances in Drug Delivery and Formulation · doi:10.2174/2667387816666220128123737 · Cited by 6 · see citing works
- Authors
- Steichen, S. D., Caldorera-Moore, M., & Peppas, N. A.
- Affiliations
- The University of Texas at Austin (US)
- Corresponding author
- Peppas, Nicholas A.
- ORCID
- Peppas, Nicholas A.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 48
- Issue
- 3
- Pages
- 416-427
- ISSN
- 0928-0987 (ISSN-L)
- PMC
- PMC3619023
- OpenAlex
- W2072997205
- Cited by
- 751
- References
- 78
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 40 · 2023: 50 · 2022: 46 · 2021: 68 · 2020: 90 · 2019: 75 · 2018: 80 · 2017: 80 · 2016: 74 · 2015: 52 · 2014: 31 · 2013: 15
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CTO PSOC U54-CA-143837, EB-00246-18)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- nanoparticle drug delivery, targeted drug delivery, cancer therapeutics, targeting moieties, tumor microenvironment, systemic toxicity, tumor physiology, chemotherapy
- MeSH terms
- Antineoplastic Agents, Delayed-Action Preparations, Humans, Models, Biological, Neoplasms, Tissue Distribution, Drug Delivery Systems, Nanoparticles, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
